Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of BI 655130 in generalized pustular psoriasis
2018-003080-56Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP) and pustular psoriasis, sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment emergent adverse events (TEAEs). Started Feb 2019; status: active.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)pustular psoriasis
Beyond the preview
Go deeper on 2018-003080-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003080-56.